AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 221 min read$CLRB

CLRB Q3'26 Earnings: revenue estimate is 0 USD

Cellectar Biosciences (CLRB) will report Q3'26 earnings on October 29. Analysts expect 0 USD revenue and a loss of 0.56 USD per share. Details are available on the company's financials page.

Original reporting
tradingview.com
Published Oct 22, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CLRB Q3'26 Earnings: revenue estimate is 0 USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$CLRBBearishLow
01

Why it matters

The zero‑revenue estimate signals possible setbacks, likely prompting short‑term sell pressure.

02

Market read

A low‑revenue earnings preview that may trigger a modest decline in CLRB shares ahead of the Oct 29 release.

03

What to watch

Potential upcoming partnership or licensing deal not yet announced could offset weak guidance.

Relevance 4/10Novelty 3/10Timing: pre‑market on Oct 29

Background

The article provides a brief earnings preview for Cellectar Biosciences, noting the scheduled announcement date and the analyst‑derived revenue and EPS estimates.

Company-level read

Ticker impact

$CLRBBearishMedium confidence
Context

Cellectar Biosciences will announce Q3'26 results on Oct 29 with a revenue estimate of $0 and EPS of -0.56.

Expected impact

downward pressure as investors price in the weak guidance

Evidence & confidence

Guidance of $0 revenue is unusually low for a biotech, indicating possible setbacks in its pipeline.

Market effects

Sector

May weigh on other small‑cap biotech stocks awaiting pipeline updates.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If the company has undisclosed pipeline milestones, the guidance could be a temporary dip.

Key entities

  • company
    Cellectar Biosciences, Inc.

    US‑listed biotech company (NASDAQ: CLRB) reporting Q3'26 earnings.

Read at source← All news

Related articles

OCT 27
$CLRBMedAI 8/10

Cellectar Reports 8-Year Complete Response With Iopofosine I 131; Stock Up

Cellectar Biosciences (CLRB) reported a case study where Iopofosine I 131 achieved an 8-year complete response in a DLBCL patient. The treatment led to full resolution of the targeted lesion. CLRB is advancing the drug for another blood cancer and expects to start a Phase 3 study in Q1 2027. The stock was up 5.79% in pre-market trading.

rttnews.com1 min
OCT 27
$CLRBMedAI 9/10

Cellectar reports 8-year remission in lymphoma case study

Cellectar Biosciences (CLRB) reported an 8-year remission in a lymphoma patient treated with iopofosine I 131. The patient achieved complete response by day 85 and has shown no disease progression since. The company plans to submit findings for publication and is advancing a Phase 3 study in Waldenström macroglobulinemia, with FDA submission expected in 2027. Iopofosine I 131 has received several FDA designations for various cancer indications.

investing.com2 min
AUG 22
$CLRBMedAI 8/10

Cellectar Biosciences Earnings Call Highlights Clinical Momentum - TipRanks.com

Cellectar Biosciences (CLRB) reported Q2 earnings, highlighting strong clinical data for iopofosine and a clear regulatory path. The CLOVER-WaM study showed high response rates in Waldenstrom’s macroglobulinemia. The company plans a Phase III trial and accelerated approval submission in 2027. Financing of up to $140M was secured, improving cash position to $34M. R&D expenses increased, widening net loss to $6.9M. Management acknowledged dilution risks and operational challenges.

tipranks.com3 min
AUG 17
$CLRBMed

Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data

Cellectar Biosciences (CLRB) reported Q2 2026 results on an earnings call, including $34.0M cash at June 30, 2026, $4.6M R&D expense, and a $6.9M net loss ($0.57/share). Management discussed Phase 3 WM site activation, targeted accelerated-approval submission in March-April 2027, CLR 125 data later in 2026/early 2027, and actinium-225 multi-sourcing. The May financing added $35M upfront plus milestone warrants up to $105M.

yahoo.com7 min